These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 7841311)
21. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease. Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809 [TBL] [Abstract][Full Text] [Related]
22. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity. Li A; Wun TC Thromb Haemost; 1998 Sep; 80(3):423-7. PubMed ID: 9759622 [TBL] [Abstract][Full Text] [Related]
23. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin. Liu Y; Stack SM; Lakka SS; Khan AJ; Woodley DT; Rao JS; Rao CN Arch Biochem Biophys; 1999 Oct; 370(1):112-8. PubMed ID: 10496984 [TBL] [Abstract][Full Text] [Related]
24. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Alban S; Gastpar R Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675 [TBL] [Abstract][Full Text] [Related]
26. Tissue factor pathway inhibitor (TFPI). Rucińska M; Gacko M; Skrzydlewski Z Rocz Akad Med Bialymst; 1997; 42 Suppl 1():118-22. PubMed ID: 9337530 [TBL] [Abstract][Full Text] [Related]
27. Transient high affinity binding of tissue factor pathway inhibitor-factor Xa complexes to negatively charged phospholipid membranes. Willems GM; Janssen MP; Salemink I; Wun TC; Lindhout T Biochemistry; 1998 Mar; 37(10):3321-8. PubMed ID: 9521652 [TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation. Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: a comparison between tissue factor pathway inhibitor and inactive factor VIIa. Valentin S; Reutlingsperger CP; Nordfang O; Lindhout T Thromb Haemost; 1995 Dec; 74(6):1478-85. PubMed ID: 8772224 [TBL] [Abstract][Full Text] [Related]
30. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184 [TBL] [Abstract][Full Text] [Related]
31. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro. Hansen JB; Huseby KR; Huseby NE; Ezban M; Nordøy A Thromb Res; 1997 Mar; 85(5):413-25. PubMed ID: 9076898 [TBL] [Abstract][Full Text] [Related]
32. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. Warshawsky I; Bu G; Mast A; Saffitz JE; Broze GJ; Schwartz AL J Clin Invest; 1995 Apr; 95(4):1773-81. PubMed ID: 7706485 [TBL] [Abstract][Full Text] [Related]
33. Cloning, expression, and characterization of mouse tissue factor pathway inhibitor (TFPI). Chang JY; Monroe DM; Oliver JA; Liles DK; Roberts HR Thromb Haemost; 1998 Feb; 79(2):306-9. PubMed ID: 9493581 [TBL] [Abstract][Full Text] [Related]
34. Peptide corresponding to the C terminus of tissue factor pathway inhibitor inhibits mesangial cell proliferation and activation in vivo. Liang W; Cheng J; Liu R; Wang JP; Mu JG; Wang QH; Wang HJ; Ma D Peptides; 2009 Dec; 30(12):2330-6. PubMed ID: 19720104 [TBL] [Abstract][Full Text] [Related]
35. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor. Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974 [TBL] [Abstract][Full Text] [Related]
36. Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies. Nagase H; Enjyoji K; Kamikubo Y; Kitazato KT; Kitazato K; Saito H; Kato H Thromb Haemost; 1997 Aug; 78(2):864-70. PubMed ID: 9268186 [TBL] [Abstract][Full Text] [Related]
37. [Tissue factor pathway inhibitor (TFPI) and its role in pathology]. Rucińska M; Gacko M; Skrzydlewski Z Postepy Hig Med Dosw; 1997; 51(4):421-30. PubMed ID: 9446103 [TBL] [Abstract][Full Text] [Related]
38. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. Abumiya T; Enjyoji K; Kokawa T; Kamikubo Y; Kato H J Biochem; 1995 Jul; 118(1):178-82. PubMed ID: 8537308 [TBL] [Abstract][Full Text] [Related]
39. Complementary DNA sequencing of canine tissue factor pathway inhibitor reveals a unique nanomeric repetitive sequence between the second and third Kunitz domains. Girard TJ; Gailani D; Broze GJ Biochem J; 1994 Nov; 303 ( Pt 3)(Pt 3):923-8. PubMed ID: 7980463 [TBL] [Abstract][Full Text] [Related]
40. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Sprecher CA; Kisiel W; Mathewes S; Foster DC Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3353-7. PubMed ID: 8159751 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]